Our Patient Support Programs and COVID-19
As the COVID-19 outbreak continues to evolve, Sanofi’s priority is the health and safety of healthcare providers, patients and employees. In line with this and working with our patient support program (PSP) providers, we have taken steps to support global efforts to reduce the spread of COVID-19 and protect our most vulnerable populations.
Sanofi remains committed to continuing our patient support program services without interruption. However, out of an abundance of caution, and in response to the growing efforts to mitigate the COVID-19 spread, we are implementing specific measures to further protect the health and safety of our healthcare providers, patients and their families.
Our PSP providers have shifted their services to provide virtual support where possible. This includes navigating reimbursement, treatment counselling, injection training and questions related to therapies. We will continue to provide home delivery of medication for relevant programs.
For patient support services that are considered essential and must be provided in-home (i.e., administration of treatment), our PSP providers will implement appropriate measures based on guidance from public health authorities, including screening questionnaires for both providers and patients, social distancing and use of personal protection equipment.
For specific information about one of our patient support programs, please contact the program directly. At this time, Sanofi does not anticipate shortages of our medications for patients resulting from the COVID-19 situation. We are working to maintain the supply of all our medicines and vaccines through close collaboration with our suppliers throughout the world. For specific information about any of our products please reach out to Sanofi Canada Medical Information services at 1-800-265-7927. For more information about the COVID-19 situation, please visit the Health Canada website.
Sanofi and our PSP partners may provide updates with actions we are taking to protect the health and safety of healthcare providers and patients. We thank you for your understanding during this time.
PSP Contact Information:
ELIGARD® Home Injection Program: 1-877-787-3228
DUPIXENT® Freedom Support Program: 1-844-216-1181
KEVZARA® Mobilize Support Program: 1-888-972-6634
MS One to One™ (AUBAGIO® and LEMTRADA®): 1-855-671-2663
MyPraluent Coach: 1-866-772-5836 or email@example.com
SYNVISC® OnTRACK: 1-800-796-7991
Rare Together Patient Support Program:
Aldurazyme® PSP: Tel.: 1-866-966-8773, Fax: 1-888-565-6345
Caprelsa® PSP and Risk Management Program: Tel. :1-855-212-3922, Fax: 1-855-212-7871
Cerdelga® PSP: Tel.: 1-866-966-8773, Fax: 1-888-565-6345
Cerezyme® PSP: Tel.: 1-866-966-8773, Fax: 1-888-565-6345
Fabrazyme® PSP: Tel.: 1-866-966-8773, Fax: 1-888-565-6345
Myozyme® PSP: Tel.: 1-866-966-8773, Fax: 1-888-565-6345
Thyrogen® PSP: Tel.: 1-877-470-7686, Fax:1-844-850-1196
REACH PSP (Jevtana®, Mozobil® and Libtayo™): 1-855-572-6634
Renagel® and Renvela® Renassist Plus: 1-866-424-8051
Rilutek® PSP: 1-866-474-5883
For any other product inquiries please contact Sanofi Canada Medical Information services at 1-800-265-7927.